SCHEMBL4747833

SCHEMBL4747833

COCCOc1nc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2)nc1C#N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP8 P40818 2/20 0.57
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 5/20 0.47
HPGD P15428 5/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ERBB2 P04626 1/20 0.42
CNR1 P21554 3/20 0.40
SQOR Q9Y6N5 2/20 0.40
NR1D1 P20393 1/20 0.39
GAA P10253 3/20 0.37
CYP1A2 P05177 3/20 0.37
CYP3A4 P08684 3/20 0.37
CYP2C9 P11712 3/20 0.37
ALOX15 P16050 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP2D6 P10635 2/20 0.37
ALOX12 P18054 1/20 0.37
LMNA P02545 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5521872 0.86 USP8 (0.43) USP8ALDH1A1KDM4EHPGDNPC1
SCHEMBL14523435 0.80 CNR1 (0.40) USP8ALDH1A1KDM4EHPGDNPC1
SCHEMBL14545311 0.80 CNR1 (0.40) USP8ALDH1A1KDM4EHPGDNPC1
SCHEMBL5520596 0.79 HRH3 (0.54) CYP2D6
SCHEMBL4695206 0.78 CNR1 (0.46) USP8ALDH1A1KDM4EHPGDNPC1
SCHEMBL14545380 0.77 CNR1 (0.45) KDM4EERBB2CNR1
SCHEMBL14545547 0.77 KDM4E (0.50) USP8ALDH1A1KDM4EHPGDNPC1
SCHEMBL4695659 0.77 USP8 (0.40) USP8ALDH1A1ERBB2CNR1CYP1A2
SCHEMBL14545312 0.76 CNR1 (0.52) ALDH1A1KDM4EHPGDSMN1; SMN2ERBB2
SCHEMBL4690341 0.76 SIGMAR1 (0.47) ALDH1A1KDM4ENPC1RAB9ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871762-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2008-01-02 EP disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
WO-2006113704-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078135-A1 Substituted heteroaryl CB1 antagonists CNR1, CNR2, OPRL1 USP8 2895/4885ALDH1A1 1492/4885KDM4E 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.